Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well epacadostat and pembrolizumab work in treating
participants with pancreatic cancer that has spread to other places in the body. Epacadostat
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving epacadostat and pembrolizumab may work better in treating participants with
pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Incyte Corporation Merck Sharp & Dohme Corp. National Cancer Institute (NCI)